Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

B cell malignancy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Payload (1) Akt (3) Apoptosis (6) Aurora Kinase (2) Bcl-2 Family (1) BMX Kinase (1) Btk (10) c-Fms (1) CD19 (2) CD20 (1) CD28 (1) CD3 (1) CDK (1) Checkpoint Kinase (Chk) (1) Dengue Virus (1) Endogenous Metabolite (1) Epigenetic Reader Domain (1) Flavivirus (1) Histone Methyltransferase (1) Interleukin Related (1) JAK (1) MALT1 (2) MDM-2/p53 (1) MEK (1) Microtubule/Tubulin (1) MNK (1) PI3K (8) PROTACs (3) Syk (1) TNF Receptor (1) Transmembrane Glycoprotein (3) Wee1 (1)
By Research Areas:	Cancer (35) Infection (1) Inflammation/Immunology (5) Metabolic Disease (1)

By Targets:

ADC Payload (1)

Akt (3)

Apoptosis (6)

Aurora Kinase (2)

Bcl-2 Family (1)

BMX Kinase (1)

Btk (10)

c-Fms (1)

CD19 (2)

CD20 (1)

CD28 (1)

CD3 (1)

CDK (1)

Checkpoint Kinase (Chk) (1)

Dengue Virus (1)

Endogenous Metabolite (1)

Epigenetic Reader Domain (1)

Flavivirus (1)

Histone Methyltransferase (1)

Interleukin Related (1)

JAK (1)

MALT1 (2)

MDM-2/p53 (1)

MEK (1)

Microtubule/Tubulin (1)

MNK (1)

PI3K (8)

PROTACs (3)

Syk (1)

TNF Receptor (1)

Transmembrane Glycoprotein (3)

Wee1 (1)

By Research Areas:

Cancer (35)

Infection (1)

Inflammation/Immunology (5)

Metabolic Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Targets Recommended: Programmed Cell Death 4 (PDCD4) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor VISTA BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-142648

MLT-985 1 Publications Verification	MALT1	Cancer
MLT-985 is a selective allosteric and orally active MALT1 inhibitor with an IC₅₀ value of 3 nM. MLT-985 can suppress cell growth and aberrant CARD11/BCL10/MALT1 complex signaling. MLT-985 can be used for the research of cancer, such as B cell malignancies .

HY-15771A

Tirabrutinib hydrochloride Maximum Cited Publications 7 Publications Verification ONO-4059 hydrochloride; GS-4059 hydrochloride	Btk Apoptosis	Inflammation/Immunology Cancer
Tirabrutinib (ONO-4059) hydrochloride is an orally active Bruton’s Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC₅₀ of 6.8 nM. Tirabrutinib hydrochloride irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib hydrochloride can be used in studies of autoimmune diseases and hematological malignancies .

HY-15771

Tirabrutinib Maximum Cited Publications 7 Publications Verification ONO-4059; GS-4059	Btk Apoptosis	Inflammation/Immunology Cancer
Tirabrutinib (ONO-4059) is an orally active Bruton’s Tyrosine Kinase (BTK) inhibitor (can cross the blood-brain barrier (BBB)), with an IC₅₀ of 6.8 nM. Tirabrutinib irreversibly and covalently binds to BTK and inhibits aberrant B cell receptor signaling. Tirabrutinib can be used in studies of autoimmune diseases and hematological malignancies .

HY-176172

BTK-IN-44	Btk	Cancer
BTK-IN-44 (Compound 10) is a potent noncovalent inhibitor of Bruton’s tyrosine kinase (BTK) with an IC₅₀ value of 24.7 nM. BTK-IN-44 interferes with signaling pathways of B cell malignancies, showing antitumor effects in lymphoma cells. BTK-IN-44 is promising for research of B cell malignancies (such as lymphoma) .

HY-168983

Lonitoclax	Bcl-2 Family	Cancer
Lonitoclax is a B-cell lymphoma 2 (Bcl-2) inhibitor. Lonitoclax has comparable anti-tumor efficacy to Venetoclax (HY-15531) in both B cell and myeloid malignancy models. Lonitoclax is promising for research of relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, and certain low-grade lymphomas .

HY-P991671

Anafiltamig	CD3 CD20 Transmembrane Glycoprotein	Cancer
Anafiltamig is a trivalent monoclonal antibody inhibitor targeting *CD79B, CD3E* and MS4A1. Anafiltamig consists of a humanized IgG1κ anti-CD79B arm and a bispecific scFv-based arm targeting CD3E and MS4A1. Anafiltamig simultaneously bridges T and B cells, activating T cells and specifically killing B cell tumors. Anafiltamig can be used for B cell malignancies such as non-Hodgkin lymphoma research .

HY-142648A

(R)-MLT-985	MALT1	Cancer
(R)-MLT-985 is the R configuration of MLT-985 (HY-142648). MLT-985 is a selective allosteric and orally active MALT1 inhibitor with an IC₅₀ value of 3 nM. MLT-985 can suppress cell growth and aberrant CARD11/BCL10/MALT1 complex signaling. MLT-985 can be used for the research of cancer, such as B cell malignancies .

HY-P991542

GBR-401	CD19	Cancer
GBR-401 is a humanized anti-CD19 monoclonal antibody with high affinity for FcγRIIIa. GBR-401 exerts a potent in vitro and in vivo cytotoxic activity against various B-cell malignancies. GBR-401 induces cell death by antibody dependent cellular cytotoxicity (ADCC) and direct killing effect. GBR-401 demonstrates potent activity of depleting malignant B cells and prolongs mice survival in multiple xenograft severe combined immunodeficiency (SCID) mice models .

HY-153536

PROTAC BTK Degrader-3	PROTACs Btk	Cancer
PROTAC BTK Degrader-3 is a potent BTK degrader with a DC₅₀ value of 10.9 nM of BTK degradation in Mino cells. PROTAC BTK Degrader-3 has the potential for B-cell malignancies, including chronic lymphoid malignancies research .

HY-10984A

(S)-Pomalidomide (S)-CC-4047	Endogenous Metabolite	Cancer
(S)-Pomalidomide ((S)-CC-4047) is an angiogenesis-inhibiting drug with growth-inhibitory activity against B-cell tumors. (S)-Pomalidomide can induce complete tumor regression in BurK_itt lymphoma cells. (S)-Pomalidomide serves as an immunomodulator with potential applications in inhibiting hematological malignancies .

HY-P991562

MDX-1411	Transmembrane Glycoprotein	Cancer
MDX-1411 is a fully human monoclonal antibody targeting CD70. MDX-1411 is capable of inducing antibody-dependent cellular cytotoxicity (ADCC). MDX-1411 can be used in the research of B-cell malignancies .

HY-174366

JMC14	c-Fms PI3K	Cancer
JMC14 is a selective and orally active PI3Kδ and CSF1R inhibitor with IC₅₀ values of 12 nM and 143 nM, respectively. JMC14 preferentially inhibits PI3Kδ-mediated signaling at the cellular level. JMC14 demonstrates potent antitumor activity against B-cell lymphomas and triple-negative breast cancer (TNBC) in both in vitro and vivo studies. JMC14 can be used for the study of antitumor immunity .

HY-109198A

Zandelisib hydrochloride ME-401 hydrochloride; PWT-143 hydrochloride	PI3K Akt	Cancer
Zandelisib (ME-401) hydrochloride is a selective, orally active, non-covalent inhibitor of PI3Kδ. Zandelisib hydrochloride can sustainably inhibit AKT phosphorylation and downstream signaling pathways. Zandelisib hydrochloride can be used in the study of malignancies such as relapsed/refractory B-cell lymphoma .

HY-109198

Zandelisib ME-401; PWT-143	PI3K Akt	Cancer
Zandelisib (ME-401) is a selective, orally active, non-covalent inhibitor of PI3Kδ. Zandelisib can sustainably inhibit AKT phosphorylation and downstream signaling pathways. Zandelisib can be used in the study of malignancies such as relapsed/refractory B-cell lymphoma .

HY-129390

Orelabrutinib 3 Publications Verification ICP-022	Btk	Cancer
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor with potential antineoplastic activity. Orelabrutinib prevents both the activation of the B-cell antigen receptor (BCR) signaling pathway and BTK-mediated activation of downstream survival pathways, inhibiting the growth of malignant B-cells that overexpress BTK .

HY-176083

ASTX295	MDM-2/p53	Cancer
ASTX295 is a selective mouse double minute 2 (MDM2) antagonist with an IC₅₀ value of <1 nM. ASTX295 specifically blocks the interaction between MDM2 and p53, reactivating wild-type (WT) TP53, and then inducing the expression of related transcriptional targets, leading to cell death and cell cycle arrest. ASTX295 is promising for research of lymphoid malignancies, such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and T-cell lymphoma .

HY-15582

Auristatin E	Microtubule/Tubulin ADC Payload	Cancer
Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .

HY-15999A

Cerdulatinib hydrochloride Maximum Cited Publications 7 Publications Verification PRT062070 hydrochloride; PRT2070 hydrochloride	Syk JAK	Cancer
Cerdulatinib hydrochloride (PRT062070) is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC₅₀s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies .

HY-149051

BGB-8035	Btk	Inflammation/Immunology Cancer
BGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC₅₀s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research .

HY-150638

PI3Kδ/γ-IN-3	PI3K Apoptosis	Cancer
PI3Kδ/γ-IN-3 (Compound 58) is a potent and orally active PI3Kδ and PI3Kγ dual inhibitor with IC₅₀s of 1 nM and 16 nM, respectively. PI3Kδ/γ-IN-3 induces tumor cell apoptosis and can be used for B-cell malignancies research .

HY-109068

Parsaclisib 1 Publications Verification INCB050465; IBI-376	PI3K	Cancer
Parsaclisib (INCB050465) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC₅₀ of 1 nM at 1 mM ATP. Parsaclisib shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib can be used for the research of relapsed or refractory B-cell malignancies .

HY-109068A

Parsaclisib hydrochloride 1 Publications Verification INCB050465 hydrochloride; IBI-376 hydrochloride	PI3K	Cancer
Parsaclisib hydrochloride (INCB050465 hydrochloride) is a potent, selective and orally active inhibitor of PI3Kδ, with an IC₅₀ of 1 nM at 1 mM ATP. Parsaclisib hydrochloride shows approximately 20000-fold selectivity over other PI3K class I isoforms. Parsaclisib hydrochloride can be used for the research of relapsed or refractory B-cell malignancies .

HY-173499

HLDA-212	Aurora Kinase Apoptosis	Cancer
HLDA-212 (Compound 43) is a bifunctional small molecule targeting HaloTag-tagged protein (Target Protein, TP) and Aurora kinase A/B (AURKA/B, Effector Protein, EP). HLDA-212 binds to TP and EP to form a stable ternary complex (TP:RIPTAC:EP), inhibiting the cell-survival function of EP and inducing apoptosis in TP-expressing cancer cells. HLDA-212 shows antiproliferative activity (GI₅₀ of 0.011 μM) in 293_HFL cells. HLDA-212 is promising for research of cancers with high TP expression (such as prostate cancer and hematological malignancies) .

HY-P5472

Tumour-associated MUC1 epitope	Transmembrane Glycoprotein	Others
Tumour-associated MUC1 epitope is a biological active peptide. (This sequence is the hallmark of MUC1 mucin. MUC1 is a highly glycosylated type I transmembrane glycoprotein with a unique extracellular domain consisting of a variable number of tandem repeats (VNTR) of this 20 amino acid peptide. It is overexpressed on the cell surface of many human adenocarcinomas and hematological malignancies, including multiple myeloma and B-cell lymphoma, making MUC1 broadly applicable target for immunotherapeutic strategies.)

HY-P991176

RG-6333 RO7443904	CD19 CD28	Cancer
RG-6333 is a bispecific agonist targeting CD19 and CD28. RG-6333 specifically recognizes and binds to the CD19 antigen on the surface of B-cell malignancies to locate tumor cells. RG-6333 activates T cells by binding to CD28, overcoming activation barriers to enhance anti-tumor immunity. RG-6333 can be used in the study of relapsed/refractory non-Hodgkin's lymphoma. The recommended isotype control is human IgG4 kappa, isotype control (HY-P99003) .

HY-175261

DHI1	CDK Wee1 Checkpoint Kinase (Chk)	Cancer
DHI1 is an anti-leukemia agent with high selectivity for Jurkat (IC₅₀ = 21.83 μM) and HL-60 (IC₅₀ = 19.14 μM) leukemia cells and has low toxicity to non-cancerous cells. DHI1 can induce G2/M phase cell arrest in Jurkat and HL-60 leukemia cells, as well as S phase arrest in HL-60 cells, and has significant effects on cell cycle signaling molecules Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasion of Jurkat and HL-60 cells by disrupting cytoskeletal actin filaments. DHI1 can be used to study hematological malignancies .

HY-158618

Aurora kinase inhibitor-14	Aurora Kinase Apoptosis	Cancer
Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC₅₀ values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia .

HY-143472

PI3Kδ-IN-11	PI3K Akt Apoptosis	Cancer
PI3Kδ-IN-11 is a highly potent and selective PI3Kδ inhibitor with IC₅₀ value of 27.5 nM. PI3Kδ-IN-11 dose-dependently blocks the activity of PI3K/Akt pathway. PI3Kδ-IN-11 can be used for researching B or T cell-related malignancies .

HY-146789

PI3Kδ/γ-IN-2	PI3K	Cancer
PI3Kδ/γ-IN-2 is a potent PI3Kδ and PI3Kγ dual inhibitor with IC₅₀s of 1 nM and 4.3 nM, respectively. PI3Kδ/γ-IN-2 has favorable oral bioavailability. PI3Kδ/γ-IN-2 has potential for battling B-cell malignancies .

HY-160141

Catadegbrutinib BGB-16673; BTK-IN-29	PROTACs Btk	Cancer
BGB-16673 (BGB-16673; BTK-IN-29) is an orally active, selectively chimeric degradation activator compound (CDAC), targeting BTK (IC₅₀=0.69 nM). BGB-16673 ligates BTK to E3 ubiquitin ligase, causing BTK to undergo polyubiquitination, which is then recognized and degraded by the proteasome, thereby exerting efficient BTK degradation activity. BGB-16673 can be used in the research of B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma .

HY-176701

PRMT5-MTA-IN-4	Histone Methyltransferase	Cancer
PRMT5-MTA-IN-4 (Compound 30) is a potent irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor (IC₅₀=8 nM). PRMT5-MTA-IN-4 blocks arginine methylation, inhibiting ribosomal RNA processing and cell cycle-related protein expression. PRMT5-MTA-IN-4 exhibits antiproliferative activity in multiple tumor cell lines (e.g., IC₅₀=0.3 μM in DLD-1 cells). PRMT5-MTA-IN-4 is promising for research of hematological malignancies, such as acute myeloid leukemia, diffuse large B-cell lymphoma .

HY-150105

Icovamenib BMF-219; Menin-MLL inhibitor 21	Epigenetic Reader Domain	Metabolic Disease Inflammation/Immunology Cancer
Icovamenib (BMF-219) is a selective, orally active, irreversible Menin inhibitor. Icovamenib forms a stable and irreversible covalent bond with Menin. Icovamenib promotes selective and controlled proliferation of beta cells and improvement of beta cell function in ex vivo human islet cultures. Icovamenib enhances glycemic control in animal diabetic models. Icovamenib induces a dose-dependent enhancement in insulin secretion potentiated by the GLP-1 RA. Icovamenib can be used for the study of multiple hematologic malignancies, solid tumors, and diabetes mellitus, such as diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM) and chronic lymphocytic leukemia and type 2 diabetes .

HY-132844

Tunlametinib HL-085	MEK	Cancer
Tunlametinib is a highly selective, orally active MEK1/2 inhibitor (IC₅₀=1.9 nM, MEK1). Tunlametinib blocks the RAS-RAF-MEK-ERK signaling pathway, arrests tumor cell cycle and promotes apoptosis. Tunlametinib potently inhibits the proliferation of RAS/RAF mutant cancer cells (such as BRAF V600E, KRAS G12C mutant cells). Tunlametinib shows synergistic anti-tumor effects with BRAF/KRAS ^G12C/SHP2 inhibitors, Docetaxel (HY-B0011). Tunlametinib can be used to study targeted therapy for RAS/RAF mutation-driven malignancies (such as melanoma, colorectal cancer, and non-small cell lung cancer) .

HY-124645

QL-X-138	Flavivirus Dengue Virus Btk MNK	Infection Cancer
QL-X-138 is a potent and selective BTK/MNK dual kinase inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC₅₀s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively. QL-X-138 also shows anti-dengue virus 2 activity, with an IC₅₀ of 3.5 μM. QL-X-138 can be used for the research of B-cell malignancies .

HY-175541

TQ-3959	PROTACs Btk	Cancer
TQ-3959 is an orally active BTK PROTAC degrader, with a DC₅₀ of 14.6 nM. TQ-3959 exerts antiproliferative activity against both wild-type BTK and C481S mutant BTK cell lines. TQ-3959 exhibits tumor growth inhibition in female NOD-SCID mice bearing TMD-8 xenografts. TQ-3959 can be used in the research on B-cell malignancies such as lymphoma.(Pink: BTK ligand (HY-150885), Blue: CRBN Ligand (HY-W733888), Black: Linker (HY-W061884), E3 ligase ligand-linker conjugate (HY-175545)) .

HY-139481

TL-895 1 Publications Verification	Btk BMX Kinase Interleukin Related TNF Receptor	Inflammation/Immunology Cancer
TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor. TL-895 is active against recombinant BTK (average IC₅₀: 1.5 nM) and inhibits only three additional kinases BLK, BMX (IC₅₀ = 1.6 nM) and TXK with IC₅₀ within tenfold of BTK activity. TL-895 inhibits BTK auto-phosphorylation at the Y223 phosphorylation site (IC₅₀: 1-10 nM). The TL-895 effectively inhibits the production of inflammatory factors such as IL-8, IL-1β, MCP-1 and TNF-α by monocytes or macrophages, and reduces the chemotactic migration of MF cells towards SDF-1. TL-895 is used be for studies of chronic lymphocytic leukemia (CLL), myelofibrosis (MF), and B-cell malignancies .

Cat. No.	Product Name	Target	Research Area